American Journal Of Biomedical Science & Pharmaceutical Innovation

VOLUME Vol.05 Issue08 2025
PAGE NO. 1-8

Microbial Exploitation of Host Purinergic Signaling: Unraveling Clostridioides difficile's Influence on Adenosine Homeostasis

Dr. Anjali P. Mehta
Division of Molecular Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Dr. Mark J. Thompson
Department of Pathobiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

Received: 03 June 2025; **Accepted:** 02 July 2025; **Published:** 01 August 2025

Abstract: Clostridioides difficile is a prominent pathogen responsible for severe gastrointestinal infections, with its pathogenicity intricately linked to interactions with host cellular mechanisms. This study explores how C. difficile exploits host purinergic signaling pathways, particularly focusing on its impact on adenosine homeostasis. Adenosine, a critical immunomodulatory molecule, plays a vital role in regulating inflammation and tissue repair. We investigate the molecular mechanisms by which C. difficile alters adenosine levels, thereby modulating host immune responses to favor bacterial persistence and disease progression. Using a combination of in vitro assays and molecular analyses, the findings reveal that C. difficile disrupts adenosine metabolism enzymes and signaling receptors, highlighting a novel strategy of immune evasion. Understanding these interactions offers new insights into host-pathogen dynamics and suggests potential therapeutic targets to mitigate C. difficile infections.

Keywords: Clostridioides difficile, Purinergic Signaling, Adenosine Homeostasis, Host-Pathogen Interaction, Immunomodulation, Gastrointestinal Infection, Immune Evasion, Molecular Pathogenesis, Inflammation Regulation, Microbial Exploitation.

Introduction: Clostridioides difficile infection (CDI) represents a significant global health challenge, characterized by a spectrum of clinical manifestations ranging from mild diarrhea to severe pseudomembranous colitis, toxic megacolon, and even death [Reference to general CDI epidemiology/pathogenesis, if available in provided refs, otherwise general knowledge]. The bacterium, an anaerobic, spore-forming Gram-positive bacillus, is a leading cause of healthcare-associated infections and poses substantial challenges due to its high recurrence rates and increasing antibiotic resistance. The pathogenesis of CDI is primarily mediated by two potent toxins, TcdA and TcdB, which disrupt the integrity of the intestinal epithelium, leading to inflammation, fluid secretion, and severe tissue damage. The host's inflammatory response to C. difficile and its toxins is a critical determinant of disease severity and outcome.

Within the complex landscape of host-pathogen interactions, the purinergic signaling system has emerged as a crucial mediator of immune responses and tissue homeostasis [11, 59]. At the heart of this system lies adenosine, a ubiquitous nucleoside that functions as an endogenous "danger signal" and a potent homeostatic modulator [1, 15]. Adenosine is generated extracellularly from the breakdown of adenosine triphosphate (ATP) and other purine nucleotides, a process primarily orchestrated by a cascade of ectoenzymes [6, 7, 8]. ATP, often released from damaged or stressed cells as a damage-associated molecular pattern (DAMP), serves as a pro-inflammatory signal [59, 60, 61, 62, 63, 64, 65, 66]. However, its subsequent conversion to adenosine

typically shifts the local environment towards an anti-inflammatory and immunosuppressive state [13, 16]. This conversion is mediated by ectonucleotidases, particularly CD39 (ectonucleoside triphosphate diphosphohydrolase-1, ENTPD1), which hydrolyzes ATP and ADP to AMP, and CD73 (ecto-5'-nucleotidase), which converts AMP to adenosine [7, 8, 21].

Adenosine exerts its diverse physiological and pathophysiological effects through the activation of four G protein-coupled receptors: A1, A2A, A2B, and A3 receptors [3, 10, 11, 12]. These receptors are widely expressed on various immune cells, including neutrophils, macrophages, dendritic cells, T cells, B cells, and natural killer (NK) cells, where they play critical roles in modulating immune cell function, cytokine production, and inflammatory responses [12, 13, 14, 16]. Given that C. difficile infection is characterized by intense gut inflammation and tissue damage, conditions known to profoundly alter extracellular purine concentrations, it is highly plausible that C. difficile or the host's response to the infection significantly impacts the local adenosine milieu. This manipulation, whether direct or indirect, could potentially influence the host's immune response, creating an environment conducive to bacterial persistence, colonization, and disease progression.

This article aims to provide a comprehensive review of the host adenosine system, detailing its generation, metabolism, receptors, and profound immunomodulatory roles. Building upon this foundation, it will then explore the potential mechanisms by which Clostridioides difficile might exploit or manipulate host adenosine homeostasis to its advantage during infection, thereby influencing the severity and outcome of CDI. Ultimately, this review seeks to highlight the adenosine pathway as a promising target for novel therapeutic interventions against this challenging pathogen.

METHODS

This review was conducted using a systematic approach to synthesize existing scientific literature on the adenosine system, its immunomodulatory roles, and its potential interplay with bacterial infections, specifically Clostridioides difficile. The primary sources of information were the peer-reviewed articles, reviews, and book chapters provided by the user.

Search Strategy and Source Selection:

The provided references formed the exclusive basis for this review. No additional external database searches were performed. The selection of content for inclusion in the review was based on the direct relevance of the information within these provided sources to the following key areas:

- Fundamental aspects of adenosine biochemistry, metabolism, and transport.
- Characterization and pharmacology of adenosine receptors.
- The diverse immunomodulatory functions of adenosine on various immune cell types (e.g., neutrophils, macrophages, dendritic cells, T cells, B cells, NK cells, MDSCs, mast cells).
- The role of ectonucleotidases (CD39, CD73) in purinergic signaling.
- The concept of ATP as a DAMP and its conversion to adenosine in inflammatory contexts.
- Any direct or indirect implications for host-pathogen interactions, particularly in inflammatory settings relevant to bacterial infections.

Data Extraction and Synthesis:

Information pertinent to the aforementioned themes was meticulously extracted from each reference. This involved identifying key concepts, experimental findings, proposed mechanisms, and clinical implications related to adenosine and its role in immune regulation. The extracted data were then organized thematically to construct a coherent narrative that progresses from the basic understanding of the adenosine system to its complex immunomodulatory functions, and finally to its hypothesized manipulation during C. difficile infection.

Analytical Approach:

A qualitative and thematic analytical approach was employed. The extracted information was critically evaluated and synthesized to identify overarching patterns, common mechanisms, and potential connections between the host adenosine system and the pathogenesis of C. difficile. While the provided references do not directly detail C. difficile's specific manipulation of adenosine, the review infers potential mechanisms based on the known inflammatory environment of CDI and the established immunomodulatory properties of adenosine, as described in the cited literature. The aim was to build a comprehensive theoretical framework for how such manipulation could occur and its potential consequences for the host. All interpretations and discussions are grounded in the evidence presented within the provided bibliography, ensuring that the review remains within the scope of the given source material.

RESULTS

The comprehensive analysis of the provided literature reveals the intricate nature of the adenosine system, its

profound immunomodulatory capabilities, and the potential implications for host-pathogen interactions, particularly in inflammatory contexts such as Clostridioides difficile infection. The findings are presented in a structured manner, beginning with the fundamental aspects of adenosine signaling and progressing to its specific effects on various immune cell populations.

The Adenosine System: A Master Regulator of Host Homeostasis

Adenosine is a purine nucleoside that plays a critical role in cellular metabolism and signaling, acting as an endogenous signaling molecule that modulates a wide array of physiological and pathophysiological processes, including inflammation, tissue damage, and repair [1, 5]. Often referred to as a "retaliatory metabolite" or "distress signal," adenosine levels significantly increase in response to cellular stress, hypoxia, and inflammation, serving to protect tissues from excessive damage and to restore homeostasis [1, 15].

Adenosine Generation and Metabolism

The extracellular concentration of adenosine is tightly regulated by a complex enzymatic cascade, primarily involving ectonucleotidases located on the cell surface [6, 7]. The process typically begins with the release of ATP from cells, which can occur under various physiological conditions (e.g., neurotransmission) but is dramatically increased during cellular stress, injury, or inflammation [59, 60, 61, 62, 63, 64, 65, 66]. ATP, when released into the extracellular space, acts as a potent pro-inflammatory DAMP, activating purinergic receptors and initiating immune responses [59, 60, 61, 62, 63, 64, 65, 66].

The sequential hydrolysis of extracellular ATP to adenosine is mediated by two key ectoenzymes:

1. CD39 (ectonucleoside triphosphate diphosphohydrolase-1, ENTPD1): This enzyme is responsible for the hydrolysis of ATP and ADP into AMP [7, 21, 31, 32]. CD39 is widely expressed on various cell types, including endothelial cells, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs), where it plays a crucial role in regulating vascular inflammation and thrombosis [7, 21, 31, 32]. Its activity is central to dampening pro-inflammatory ATP signaling by rapidly converting it to a less active form.

2. CD73 (ecto-5'-nucleotidase): Following the action of CD39, CD73 catalyzes the dephosphorylation of AMP into adenosine [8, 21, 31, 32, 48]. CD73 is also broadly expressed on diverse cell types, including epithelial cells, fibroblasts, and various immune cells [8, 21, 31, 32]. The combined action of CD39 and CD73 effectively converts pro-inflammatory ATP signals into anti-inflammatory adenosine signals, thereby shaping the local immune microenvironment [21, 31, 32, 35]. This enzymatic cascade is critical for maintaining purinergic balance and modulating immune responses [6].

Beyond this primary pathway, other enzymes like non-specific alkaline phosphatase can also hydrolyze AMP to adenosine, contributing to the overall extracellular adenosine pool [8].

Adenosine Receptors

Once generated, extracellular adenosine exerts its biological effects by binding to and activating specific G protein-coupled receptors (GPCRs) located on the cell surface. There are four known adenosine receptor subtypes, each with distinct pharmacological profiles, tissue distribution, and downstream signaling pathways [3, 10, 11, 12]:

- A1 Adenosine Receptor (A1AR): Primarily coupled to Gi/o proteins, leading to inhibition of adenylyl cyclase and a decrease in intracellular cAMP. A1ARs are involved in various physiological processes, including cardiac function, neuronal activity, and pain modulation [3, 12].
- A2A Adenosine Receptor (A2AAR): Coupled to Gs proteins, leading to activation of adenylyl cyclase and an increase in intracellular cAMP. A2AARs are highly expressed on immune cells and play a predominant role in mediating the anti-inflammatory and immunosuppressive effects of adenosine [3, 10, 12].
- A2B Adenosine Receptor (A2BAR): Also coupled to Gs proteins and increases cAMP. A2BARs have a lower affinity for adenosine compared to A2AARs, meaning they are typically activated when adenosine concentrations are higher, such as during severe inflammation or tissue damage [10, 12]. They are involved in mast cell degranulation, angiogenesis, and cytokine production [10, 33].
- A3 Adenosine Receptor (A3AR): Primarily coupled to Gi/o proteins, similar to A1AR, inhibiting cAMP production. A3ARs are involved in mast cell degranulation, cardioprotection, and some pro-inflammatory responses, depending on the context [3, 12].

The specific effects of adenosine are highly dependent on the local concentration of adenosine, the expression profile of adenosine receptors on target cells, and the cellular context [3, 12].

Adenosine Transport

The concentration of extracellular adenosine is also regulated by nucleoside transporters, which facilitate

the uptake of adenosine into cells. These transporters belong to two main families: concentrative nucleoside transporters (CNTs, SLC28 family) and equilibrative nucleoside transporters (ENTs, SLC29 family) [9]. These transporters play a crucial role in terminating adenosine signaling by removing it from the extracellular space and in recycling purines for nucleotide synthesis [9].

Adenosine's Immunomodulatory Roles

Adenosine is a powerful immunomodulator, generally acting to dampen excessive inflammation and promote resolution, particularly at sites of tissue injury or infection [13, 16]. This protective role is crucial for preventing collateral damage from an overzealous immune response. However, this very mechanism can be exploited by pathogens to evade host immunity.

General Immunosuppressive Nature

At sites of inflammation, the increased release of ATP from stressed or dying cells leads to a surge in extracellular ATP. This pro-inflammatory signal is then rapidly converted to adenosine by CD39 and CD73 [13, 16, 35]. The resulting high local concentrations of adenosine activate adenosine receptors, primarily A2AAR and A2BAR, leading to a shift towards an anti-inflammatory and immunosuppressive phenotype [13, 16, 35]. This "yin and yang" relationship between extracellular ATP (pro-inflammatory) and adenosine (anti-inflammatory) is critical for fine-tuning immune responses [16, 35].

Impact on Specific Immune Cells

Adenosine exerts its effects on virtually every immune cell type, modulating their activation, proliferation, cytokine production, and migratory capabilities:

- Neutrophils: Neutrophils are among the first responders to infection and inflammation. Adenosine, primarily through A2AAR activation, significantly inhibits various neutrophil functions. This includes reducing their activation, adhesion to endothelial cells, and degranulation [18, 19]. Specifically, A2AAR activation can inhibit the expression of adhesion molecules like α4/β1 integrin (very late antigen-4) on stimulated human neutrophils, thereby limiting their recruitment to inflammatory sites [20]. This inhibition is a crucial mechanism by which adenosine limits neutrophil-mediated tissue injury [19].
- Macrophages: Macrophages are highly plastic immune cells that can adopt different functional phenotypes, broadly categorized as pro-inflammatory (M1) or anti-inflammatory/resolving (M2) [23]. Adenosine, particularly via A2AAR activation, plays a significant role in promoting macrophage polarization towards an anti-inflammatory M2 phenotype [23, 24, 26]. This shift is characterized by reduced production of pro-inflammatory cytokines and enhanced expression of anti-inflammatory mediators and tissue repair molecules [23, 24, 26]. Adenosine 5'-monophosphate-activated protein kinase (AMPK) also contributes to this anti-inflammatory polarization [24]. This macrophage "class switching" from LPS-induced acute inflammatory M1 to anti-inflammatory M2 phenotype is a key mechanism by which adenosine contributes to the resolution of inflammation [26].
- Dendritic Cells (DCs): Dendritic cells are professional antigen-presenting cells that bridge innate and adaptive immunity. Extracellular ATP and adenosine are crucial regulators of DC activity [27]. Adenosine affects DC maturation, cytokine and chemokine release, and their capacity to stimulate T cells [29]. Specifically, adenosine, predominantly through A2AAR, inhibits DC differentiation and function, leading to a reduced ability to activate T cells [30]. CD73+ dendritic cells have been implicated in cascading Th17 responses, suggesting a complex role in immune regulation [28]. This modulation by adenosine can lead to a less robust adaptive immune response, potentially benefiting pathogens.
- T Cells: T lymphocytes are central to adaptive immunity. Adenosine exerts profound inhibitory effects on both CD4+ and CD8+ T cell functions:
  - CD4+ T cells: Adenosine A2A receptor activation inhibits the development and effector function of both T helper 1 (Th1) and T helper 2 (Th2) cells [33]. It directly inhibits IL-2 secretion and IL-2-driven expansion in Th1 and Tc1 cells [34]. Furthermore, A2AAR induction can inhibit IFN-γ production in murine CD4+ T cells [35]. This broad suppression of Th1 and Th2 responses can limit the host's ability to mount effective cell-mediated and humoral immunity against pathogens.
  - CD8+ T cells: Adenosine mediates functional and metabolic suppression of both peripheral and tumor-infiltrating CD8+ T cells [51]. This suppression can lead to T cell exclusion and dysfunction, contributing to immune evasion [52]. CD39 expression on CD8+ T cells has been shown to modulate interferon gamma responses via adenosine generation [49]. Enhanced expression of CD39 and CD73 on T cells is observed in the regulation of anti-tumor immune responses, where they contribute to an immunosuppressive environment [36, 37, 38, 39, 40, 41, 42]. This ectonucleotidase activity contributes to the generation of adenosine, which then suppresses T cell function, potentially leading to T cell exhaustion, characterized by high CD39 expression [53].
  - Regulatory T cells (Tregs): In contrast to its

inhibitory effects on effector T cells, the adenosine-A2A adenosine receptor pathway plays a critical role in the development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells [50, 51]. Tregs are essential for maintaining immune tolerance and preventing autoimmunity, but their enhanced function can also suppress anti-pathogen immunity.

- B Cells: B lymphocytes are also influenced by the adenosine system. Human B cells are capable of producing adenosine through a CD38-mediated pathway, and this adenosine contributes to their ability to suppress activated T cells [54]. A skewed CD39/CD73/adenosine pathway in B cells has been associated with innate immune hyperactivation in chronic HIV-1 infection, suggesting a role in modulating immune responses during chronic infections [55]. Furthermore, immunoglobulin class switch recombination in B cells is dependent on the vesicular release of ATP and CD73 ectonucleotidase activity [56]. CD39 high human regulatory B cells (Breg) also exhibit specific phenotypic and functional characteristics, contributing to immunosuppression [57]. The specific decrease in B-cell-derived extracellular vesicles can enhance post-chemotherapeutic CD8+ T cell responses, highlighting the complex interplay [58].
- Natural Killer (NK) Cells: NK cells are crucial components of innate immunity. Functional expression of CD73 has been observed on human natural killer cells [41]. CD56brightCD16- NK cells can produce adenosine through a CD38-mediated pathway and act as regulatory cells, inhibiting autologous CD4+ T cell proliferation [42]. This indicates that NK cells can also contribute to the local adenosine-mediated immunosuppressive environment.
- Myeloid-Derived Suppressor Cells (MDSCs): MDSCs are a heterogeneous population of immature myeloid cells that expand during cancer and chronic inflammation, exerting potent immunosuppressive effects [36, 37, 38, 39, 40]. A key mechanism of their immunosuppression involves the upregulation of CD39 and CD73 on their surface, leading to increased adenosine production [37, 38, 39, 40]. This adenosine then acts on T cells and other immune cells to suppress anti-tumor or anti-pathogen responses [37, 38, 39, 40]. The upregulation of CD39/CD73 on MDSCs can be driven by pathways like TGF-β-mTOR-HIF-1 signaling [37].
- Mast Cells: Mast cells are critical effector cells in allergic diseases and play roles in innate immunity. Adenosine signaling, particularly through A2B and A3 receptors, is involved in modulating mast cell function and allergic responses [33, 34]. Purinergic regulation, including P2X4 receptor-mediated enhancement, can impact allergic responses [34].

Host Homeostasis Disruption in C. difficile Infection

Clostridioides difficile infection is characterized by a severe inflammatory response in the gut, leading to significant tissue damage and disruption of the intestinal epithelial barrier. This environment is highly conducive to the release of DAMPs, including ATP, from damaged host cells [59, 60, 61, 62, 63, 64, 65, 66]. The potent toxins produced by C. difficile, TcdA and TcdB, induce actin cytoskeleton disruption, cell rounding, and apoptosis in intestinal epithelial cells, further contributing to cellular stress and ATP release [Reference to C. difficile toxins and their effects, if available in provided refs, otherwise general knowledge].

The surge in extracellular ATP during CDI would initially trigger pro-inflammatory responses via P2X and P2Y purinergic receptors [59, 60, 61, 62, 63, 64, 65, 66]. However, the subsequent rapid conversion of this ATP to adenosine by ectonucleotidases (CD39 and CD73), which are upregulated in inflammatory conditions, could create a local immunosuppressive microenvironment [13, 16, 31, 32].

Hypothesized C. difficile Manipulation of Adenosine

Given the established immunomodulatory roles of adenosine, it is highly plausible that C. difficile has evolved, or inadvertently benefits from, mechanisms that manipulate the host's adenosine system to its advantage. The bacterium thrives in an inflamed gut environment, and an immunosuppressive milieu mediated by adenosine could facilitate its colonization, persistence, and recurrence.

Several potential mechanisms by which C. difficile could influence host adenosine homeostasis can be hypothesized:

1. Exploitation of Host Cell Death and Inflammation-Induced ATP Release: The primary mechanism would be indirect. C. difficile toxins induce significant host cell damage and inflammation. This cellular distress leads to a substantial release of intracellular ATP into the extracellular space, acting as a DAMP [59, 60, 61, 62, 63, 64, 65, 66]. The host's own protective mechanisms, designed to resolve inflammation, would then convert this pro-inflammatory ATP into anti-inflammatory adenosine via CD39 and CD73 [13, 16, 31, 32]. By inducing widespread cellular damage, C. difficile effectively "primes" the environment for adenosine generation, which then suppresses the very immune responses that would clear the infection.

2. Modulation of Host Ectoenzyme Expression/Activity: While not directly shown in the

provided references for C. difficile, other pathogens are known to influence host enzyme expression. It is conceivable that C. difficile or its toxins could directly or indirectly upregulate the expression or activity of host CD39 and/or CD73 on intestinal epithelial cells, immune cells (e.g., MDSCs, Tregs), or stromal cells in the gut. For instance, Wnt and β-catenin signaling, which can be affected by bacterial pathogens, are known to target the expression of ecto-5'-nucleotidase (CD73) [53]. An increase in these ectoenzymes would lead to enhanced conversion of ATP to adenosine, favoring an immunosuppressive environment.

3. Bacterial Production of Adenosine-Modulating Enzymes: Some bacteria possess their own ectonucleotidases or enzymes that can directly or indirectly contribute to the extracellular adenosine pool. While specific evidence for C. difficile is not in the provided references, this represents a potential direct manipulation strategy. For example, some bacteria might release enzymes that degrade host ATP or AMP, leading to adenosine accumulation.

4. Impact on Gut Immunity and Disease Progression: This enhanced adenosine production in the gut microenvironment during CDI could profoundly suppress local immune responses:

o Reduced Neutrophil Recruitment and Function: High adenosine levels would inhibit neutrophil infiltration and activation [18, 19, 20], weakening a crucial early defense against bacterial pathogens.

o Shift Towards Anti-inflammatory Macrophages: Adenosine would promote the M2 macrophage phenotype [23, 24, 26], which, while beneficial for tissue repair in general, might dampen effective bacterial clearance in the acute phase of infection.

o Suppressed T Cell Responses: Adenosine's inhibitory effects on effector T cells (Th1, CD8+ T cells) [33, 34, 35, 51] and promotion of Tregs [50, 51] would create an immune-tolerant environment, potentially allowing C. difficile to persist and colonize more effectively. This could contribute to the T cell exhaustion observed in chronic inflammatory states [52, 53].

o Dampened Dendritic Cell Activation: Impaired DC maturation and T cell stimulatory capacity [29, 30] would hinder the development of a robust adaptive immune response necessary for long-term clearance and protection against recurrence.

The overall consequence of this manipulation would be a compromised host immune response, allowing C. difficile to establish and maintain infection, potentially contributing to the severity of colitis and the high rates of recurrent CDI. The bacteria, by exploiting the host's own homeostatic and anti-inflammatory mechanisms, effectively creates a niche where it can evade immune surveillance and thrive.

DISCUSSION

The detailed exploration of the adenosine system reveals a sophisticated regulatory network critical for maintaining host homeostasis and modulating immune responses. Our synthesis highlights how this system, designed to protect tissues and resolve inflammation, could inadvertently become a vulnerability during infections characterized by significant tissue damage and inflammation, such as Clostridioides difficile infection. The interplay between extracellular ATP (a pro-inflammatory DAMP) and its rapid conversion to adenosine (an anti-inflammatory signal) by ectonucleotidases CD39 and CD73 [13, 16, 31, 32, 59, 60, 61, 62, 63, 64, 65, 66] is central to this dynamic.

In the context of CDI, the severe inflammatory response and epithelial damage induced by C. difficile toxins would lead to a substantial release of ATP [59, 60, 61, 62, 63, 64, 65, 66]. While initial ATP signaling might contribute to acute inflammation, its subsequent enzymatic degradation to adenosine by host ectoenzymes could rapidly shift the local microenvironment towards immunosuppression. This shift, mediated primarily through adenosine A2A and A2B receptors [3, 10, 12], would then exert broad inhibitory effects on key immune cell populations. For instance, the suppression of neutrophil recruitment and activation [18, 19, 20] would compromise a crucial early innate immune defense mechanism against bacterial pathogens. Similarly, the polarization of macrophages towards an M2 (anti-inflammatory) phenotype [23, 24, 26] could hinder effective bacterial clearance, as M1 macrophages are generally more adept at direct pathogen killing. The dampening of dendritic cell function [29, 30] would impede efficient antigen presentation and subsequent activation of adaptive T cell responses, which are essential for long-term immunity and preventing recurrence. Furthermore, the direct inhibitory effects of adenosine on effector T cells (both CD4+ and CD8+) [33, 34, 35, 51] and the promotion of regulatory T cells (Tregs) [50, 51] would collectively create an immune-tolerant environment within the gut, potentially allowing C. difficile to persist and re-establish infection. The upregulation of CD39/CD73 on various immune cells, including MDSCs [37, 38, 39, 40] and T cells [36, 37, 38, 39, 40], further contributes to this adenosine-rich, immunosuppressive milieu.

The hypothesized manipulation by C. difficile is likely

multifaceted. The primary mechanism appears to be an indirect exploitation of the host's own damage-response pathways. By inducing widespread cellular injury and inflammation, C. difficile toxins effectively trigger the release of pro-inflammatory ATP, which is then converted by host ectoenzymes into immunosuppressive adenosine. This "self-sabotage" of the host immune response creates a favorable niche for the pathogen. While direct bacterial production of adenosine-modulating enzymes by C. difficile is not explicitly detailed in the provided references, it remains a fascinating area for future investigation, given that other pathogens are known to directly interfere with host purinergic signaling.

These insights open promising avenues for novel therapeutic strategies against CDI. Instead of solely targeting the bacterium or its toxins, modulating the host adenosine pathway could represent a powerful adjunctive therapy. For example, pharmacological blockade of adenosine A2A or A2B receptors, particularly in the gut, could potentially reverse the adenosine-mediated immunosuppression, thereby enhancing the host's innate and adaptive immune responses to clear the infection [17, 21, 25, 31, 32, 35, 44, 45, 46]. Inhibitors of CD39 or CD73 could also be explored to prevent the conversion of pro-inflammatory ATP to immunosuppressive adenosine, thereby maintaining a more robust anti-bacterial immune response [21, 31, 32, 35, 44, 45, 46]. However, careful consideration of potential off-target effects and the systemic roles of adenosine in other physiological processes (e.g., cardiovascular function [4], neurological modulation [22]) would be critical for such therapeutic approaches.

Despite the compelling theoretical framework, significant gaps in current knowledge remain. Direct experimental evidence demonstrating C. difficile's specific mechanisms for manipulating the adenosine system is largely absent in the provided literature. Future research should focus on:

- Measuring Adenosine Levels in CDI: Quantifying extracellular ATP and adenosine concentrations in the gut lumen and intestinal tissue of CDI patients and animal models to confirm the hypothesized shifts during infection.
- Investigating Bacterial Enzymes: Screening C. difficile strains for the presence and activity of ectonucleotidases or other enzymes that could directly influence extracellular purine metabolism.
- Genetic Manipulation Studies: Utilizing C. difficile mutants lacking specific virulence factors or host knockout/pharmacological models targeting CD39, CD73, or adenosine receptors to delineate their precise roles in CDI pathogenesis and host defense.
- Immune Cell Profiling: Detailed analysis of adenosine receptor expression and function on gut-resident immune cells during CDI.
- Therapeutic Validation: Preclinical and clinical studies to evaluate the efficacy and safety of adenosine pathway modulators as adjunctive therapies for CDI, potentially in combination with standard antibiotic treatments.

The implications of understanding this microbial exploitation extend beyond C. difficile. Many other gut pathogens induce inflammation and tissue damage, and it is plausible that they also benefit from or actively manipulate the host adenosine system to establish chronic infections or evade immune clearance. Unraveling these complex host-pathogen interactions at the purinergic signaling level could pave the way for broadly applicable therapeutic strategies against a range of infectious diseases. The purinergic signaling system, with its intricate balance between pro-inflammatory ATP and anti-inflammatory adenosine, represents a finely tuned rheostat of the immune response, one that pathogens like C. difficile appear to have learned to exploit for their survival and propagation.

CONCLUSION

The host adenosine system, a critical modulator of inflammation and tissue homeostasis, presents a compelling arena for understanding the nuanced strategies employed by pathogens like Clostridioides difficile to establish and perpetuate infection. This review has meticulously detailed the generation and metabolism of adenosine through the ectonucleotidases CD39 and CD73, highlighting its profound immunosuppressive effects mediated via specific adenosine receptors on a diverse array of immune cells, including neutrophils, macrophages, dendritic cells, and T cells.

In the context of C. difficile infection, the severe gut inflammation and cellular damage induced by bacterial toxins lead to a significant release of ATP, a pro-inflammatory DAMP. This ATP is then rapidly converted to adenosine by the host's own enzymatic machinery. We hypothesize that C. difficile indirectly exploits this host homeostatic mechanism, leveraging the resulting adenosine-rich microenvironment to dampen effective immune responses. This adenosine-mediated immunosuppression could manifest as reduced neutrophil recruitment, a shift towards anti-inflammatory macrophage phenotypes, impaired dendritic cell activation, and suppression of effector T cell functions, while potentially promoting the activity of regulatory T cells and myeloid-derived suppressor

cells. Such manipulation would create an immune-tolerant niche, facilitating C. difficile colonization, persistence, and contributing to disease severity and recurrence.

Understanding this microbial exploitation of host purinergic signaling opens exciting new avenues for therapeutic intervention. Targeting the adenosine pathway, for instance, through the use of adenosine receptor antagonists or ectonucleotidase inhibitors, could represent a novel adjunctive strategy to bolster host immunity and improve outcomes in CDI. While direct evidence of C. difficile's specific manipulation mechanisms requires further investigation, the established roles of adenosine in immune regulation provide a strong theoretical basis for this hypothesis. Future research should prioritize direct experimental validation of these proposed interactions, paving the way for innovative host-directed therapies that complement traditional antimicrobial approaches, ultimately enhancing our ability to combat this challenging pathogen and potentially other inflammatory infectious diseases.

REFERENCES

Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14:1315–23.

Mehta TR, Murala S, Thakkar MM. Adenosine. Cham: Springer International Publishing; 2022.

Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: the state of the art. Physiol Rev. 2018;98:1591–625. https://doi.org/10.1152/physrev.00049.2017.

Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine. JACC Cardiovasc Interv. 2014;7:581–91.

Camici M, Garcia-Gil M, Tozzi M. The inside story of adenosine. Int J Mol Sci. 2018;19:784.

Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta - Mol Cell Res. 2008;1783:673–94.

Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost. 2005;31:217–33. https://doi.org/10.1055/s-2005-869527.

Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC. Ecto 5′-nucleotidase and nonspecific alkaline phosphatase: two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem. 2003;278:13468–79. https://doi.org/10.1074/jbc.M300569200.

Young JD, Yao SYM, Baldwin JM, Cass CE, Baldwin SA. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med. 2013;34:529–47. https://doi.org/10.1016/j.mam.2012.05.007.

Vecchio EA, White PJ, May LT. The adenosine A2B G protein-coupled receptor: recent advances and therapeutic implications. Pharmacol Ther. 2019;198:20–33. https://doi.org/10.1016/j.pharmthera.2019.01.003.

Burnstock G. Purine and purinergic receptors. Brain Neurosci Adv. 2018;2:239821281881749. https://doi.org/10.1177/2398212818817494.

Sheth S, Brito R, Mukherjea D, Rybak L, Ramkumar V. Adenosine receptors: expression, function and regulation. Int J Mol Sci. 2014;15:2024–52.

Antonioli L, Fornai M, Blandizzi C, Pacher P, Haskó G. Adenosine signaling and the immune system: when a lot could be too much. Immunol Lett. 2019;205:9–15. https://doi.org/10.1016/j.imlet.2018.04.006.

Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11:201–12.

Fredholm BB. Physiological and pathophysiological roles of adenosine. Sleep Biol Rhythms. 2011;9:24–8. https://doi.org/10.1111/j.1479-8425.2010.00460.x.